Indoleamine 2,3-dioxygenase 1 (IDO1)

Overview

Indoleamine 2,3-dioxygenase 1 (IDO1) is a protein-coding gene that encodes an enzyme involved in tryptophan catabolism along the kynurenine pathway. In biomedical research, IDO1 is widely recognized as an immunoregulatory factor because its activity can contribute to local tryptophan depletion and the accumulation of immunosuppressive Metabolites, thereby shaping T-cell responses and broader tumor immune microenvironments. For this reason, IDO1 is often discussed as a non-classical immune checkpoint rather than a conventional receptor-ligand checkpoint.

In cancer and inflammatory disease contexts, IDO1 has been studied as a mechanism of immune escape and treatment resistance. It is frequently considered alongside pathways involving STAT1, dendritic cell activation, STING1 signaling, and PD-L1-mediated immune suppression. Recent work has also linked IDO1 to mitochondrion-associated signaling and to the immunosuppressive behavior of cancer-associated fibroblast-rich tumor stroma, underscoring its relevance in breast cancer and other solid tumors.

Recent Publications Summary

Recent publications continued to position Indoleamine 2,3-dioxygenase 1 (IDO1) as a central immunometabolic target in cancer and inflammatory disease, with multiple studies focusing on its kynurenine-pathway activity and its role in immune escape. In breast cancer, IDO1 was highlighted as a prognosis-related core target in a network pharmacology and machine-learning analysis of Schisandrin A, with immune infiltration analysis suggesting a role in shaping the tumor immune microenvironment and molecular docking indicating binding affinity to IDO1 42220063Jun. A separate review of breast cancer immune checkpoints also emphasized IDO1 as a non-classical checkpoint that mediates immune escape through metabolic and signaling pathways distinct from PD-1/PD-L1 42059928Apr. In parallel, a reproducible virtual screening framework was developed specifically for IDO1 inhibitor discovery, using scaffold-aware machine learning, ensemble docking, and molecular dynamics to prioritize candidate inhibitors from curated ChEMBL data and FDA-approved drugs 42210816May.

Several studies reported direct pharmacologic inhibition of IDO1 and downstream suppression of kynurenine production. Triazole analogues were synthesized as selective IDO1 inhibitors, with compound 3b showing submicromolar enzymatic potency, strong selectivity over IDO2 and TDO, reduced kynurenine production, restoration of IL-2 activity, and increased apoptosis in cancer cells 41856068Mar. In another cancer immunotherapy approach, co-delivery of a STING agonist and an IDO1 inhibitor in a nanomedicine enhanced dendritic cell maturation, antigen cross-presentation, cytokine secretion, and cytotoxic T-cell priming, producing stronger antitumor effects than monotherapies or simple physical combinations 41702511Feb. A related photochemotherapy study in triple-negative breast cancer used copper peroxide nanoparticles to amplify reactive oxygen species-mediated damage and reported that the resulting immunogenic cell death synergized with checkpoint inhibition by relieving IDO1-mediated immunosuppression 41525757Jan.

Beyond oncology, IDO1 was also linked to inflammatory and metabolic regulation in several non-cancer settings. In rheumatoid arthritis, Erzhi pill was reported to enhance methotrexate efficacy in bone homeostasis by activating the IDO1-KYN-AhR pathway; the combination improved osteoblast differentiation and function, suppressed osteoclastogenesis, and reduced bone destruction in a collagen-induced arthritis rat model, while knockdown or inhibition of IDO1 or AhR reversed these effects 42208105May. In depressive-like behavior, a polysaccharide from Polygonatum sibiricum stems and leaves was associated with restoration of tryptophan metabolism through suppression of the IDO1-mediated kynurenine pathway and promotion of serotonin synthesis, alongside gut microbiota remodeling 42212449May. In influenza A virus-induced acute lung injury, a phenolic fraction of Elsholtzia penduliflora was reported to ameliorate disease by inhibiting the IDO-1-mitochondria-STAT1 signaling axis 41794257Mar.

IDO1 was also studied in cell therapy and transplantation contexts. In insulin-producing cells derived from human amniotic epithelial stem cells, METTL3 overexpression was investigated as a means to improve transplantation efficacy in diabetic mice by activating the IDO1-kynurenine pathway; the study assessed graft survival, endogenous islet apoptosis, and local immune infiltration, and used kynurenine and 1-methyltryptophan rescue experiments to probe causality 42406422Jul. Across these publications, IDO1 emerged as a recurring target for modulating tryptophan metabolism, immune suppression, and tissue outcomes in cancer, autoimmune disease, neurobehavioral models, infection, and cell replacement therapy 42406422Jul42208105May42212449May41794257Mar.

What Changes, What Holds

1. IDO1 remains a validated immunometabolic target, with added support for inhibitor discovery and breast-cancer relevance
REINFORCES Recent work strengthens the established view of IDO1 as a non-classical immune checkpoint and cancer target by tying it again to immune escape, tumor microenvironment shaping, and druggability in breast cancer 42220063Jun42059928Apr. The virtual-screening study does not change what IDO1 is understood to do; it mainly improves how candidate inhibitors can be found and prioritized 42210816May.

2. Direct inhibition of IDO1 continues to look therapeutically useful, but the new delivery and combination strategies extend rather than replace the baseline
REINFORCES These studies support the existing model that blocking IDO1 lowers kynurenine output and relieves immunosuppression, with downstream gains in T-cell function and antitumor activity 41856068Mar41702511Feb. The photochemotherapy result adds another context in which IDO1 suppression can cooperate with immunogenic cell death, but it does not overturn the established mechanism; it broadens the ways that mechanism may be exploited 41525757Jan.

3. IDO1 is now implicated in bone, mood, and lung-injury biology beyond cancer
NEW DIRECTION Erzhi pill’s effect in arthritis points to the IDO1-KYN-AhR axis as a mediator of bone protection, which is outside the Overview’s cancer/inflammation framing and adds a new tissue outcome to IDO1 biology 42208105May. The depression and influenza findings similarly extend IDO1 into neurotransmitter balance and acute lung injury, while leaving the baseline account of immune suppression intact 42212449May41794257Mar.

4. IDO1-linked kynurenine signaling may be leveraged to improve cell replacement outcomes
NEW DIRECTION METTL3-driven activation of the IDO1-kynurenine pathway in transplanted insulin-producing cells suggests a pro-graft use for IDO1 biology that the Overview does not cover 42406422Jul. That sits alongside, rather than against, the established immunosuppressive role of IDO1: here the same pathway is being used to support graft survival and reduce local rejection pressure, but the evidence remains preclinical and needs independent confirmation 42406422Jul.

Overview update candidates: IDO1 as a target in bone homeostasis/arthritis; depressive-like behavior; influenza-associated lung injury; and transplantation/graft survival.